US EditionPublished • loading... • Updated
MARABIO LAUNCHES FIRST-EVER BLOOD TEST FOR MATERNAL AUTOANTIBODY RELATED AUTISM
The MAR-Autism Test identifies maternal autoantibodies linked to up to 20% of autism cases, supporting earlier diagnosis and intervention, MARAbio said.
- MARAbio's Salt Lake City launch introduces the MAR-Autism Test, the first blood test to identify maternal autoantibodies linked to autism risk, with no specific launch date provided.
- Judy Van de Water, PhD, led more than two decades of UC Davis MIND Institute research that spawned MARAbio, founded to provide scientific answers and peace of mind for parents of children on the autism spectrum.
- Researchers say MARA is caused by maternal autoantibodies that cross the placenta, disrupt fetal brain development, and clinical testing showed the MAR-Autism Test has specificity of 99% or greater.
- Healthcare providers across most of the U.S. can now order the MAR-Autism Test for eligible women before pregnancy or after birth, but MARAbio cautions it is not validated for use during pregnancy.
- MARA may account for up to 1 in 5 individuals with autism, and MARAbio Systems is evaluating therapeutics after raising $19.1 million in Series A financing.
Insights by Ground AI
13 Articles
13 Articles
MARAbio introduces MAR-Autism Test to detect maternal autoantibodies
MARAbio Systems has commercially introduced a new blood test for identifying maternal autoantibody related autism.The post MARAbio introduces MAR-Autism Test to detect maternal autoantibodies appeared first on Medical Device Network.
Coverage Details
Total News Sources13
Leaning Left1Leaning Right0Center7Last UpdatedBias Distribution87% Center
Bias Distribution
- 87% of the sources are Center
87% Center
13%
C 87%
Factuality
To view factuality data please Upgrade to Premium
